Joanne V Williamson

US Patent:

43352103, Jun 15, 1982

Filed:

Feb 11, 1981

Appl. No.:

6/233564

Inventors:

Alton Meister - New York NY
Joanne M. Williamson - Roosevelt Island NY

Assignee:

Cornell Research Foundation - Ithaca NY

International Classification:

C12P 1312

US Classification:

435113

Abstract:

L-2-oxothiazolidine-4-carboxylate, a sulfur analog of 5-oxoproline, is cleaved by the enzyme 5-oxo-L-prolinase to form cysteine, thus providing the basis for a cysteine delivery system by the addition of L-2-oxothiazolidine-4-carboxylate to base amino acid solutions or by injecting it directly into in vivo cells.

US Patent:

46650822, May 12, 1987

Filed:

Jun 27, 1985

Appl. No.:

6/750043

Inventors:

Alton Meister - New York NY
Joanne M. Williamson - Roosevelt Island NY

Assignee:

Cornell Research Foundation - Ithaca NY

International Classification:

A61K 31425
A61K 3123

US Classification:

514365

Abstract:

L-2-oxothiazolidine-4-carboxylate, a sulfur analog of 5-oxoproline, is cleaved by the enzyme 5-oxo-L-prolinase to form cysteine, thus providing the basis for a cysteine delivery system by the addition of L-2-oxothiazolidine-4-carboxylate to base amino acid solutions or by injecting it directly into in vivo cells.

US Patent:

44381247, Mar 20, 1984

Filed:

Apr 15, 1982

Appl. No.:

6/368905

Inventors:

Alton Meister - New York NY
Joanne M. Williamson - Roosevelt Island NY

Assignee:

Cornell Research Foundation, Inc. - Ithaca NY

International Classification:

A61K 31195

US Classification:

424270

Abstract:

L-2-oxothiazolidine-4-carboxylate, a sulfur analog of 5-oxoproline, is cleaved by the enzyme 5-oxo-L-prolinase to form cysteine, thus providing the basis for a cysteine delivery system by the addition of L-2-oxothiazolidine-4-carboxylate to base amino acid solutions or by injecting it directly into in vivo cells.

US Patent:

54948959, Feb 27, 1996

Filed:

Jul 22, 1993

Appl. No.:

8/096942

Inventors:

Maria L. Garcia - Edison NJ
Gloria C. Koo - Woodbridge NJ
Reid J. Leonard - Westfield NJ
Chiu-Chuan S. Lin - Holmdel NJ
Robert S. Slaughter - Chatham NJ
Scott P. Stevens - Westfield NJ
Joanne M. Williamson - Cranford NJ

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

A61K 3817
C07K 14435

US Classification:

514 12

Abstract:

A thirty-nine amino acid peptide, Margatoxin (MgTX), is purified to homogeneity from venom of the scorpion Centruroides margaritatus. The gene encoding MgTX is constructed and this gene is expressed in E. coli, to produce recombinant MgTX. MgTX is a potent and selective inhibitor of a voltage-dependent K. sup. + channel present in human lymphocytes. MgTX exhibits immunosuppressant activity with human T-lymphocytes, and is useful as an immunosuppressant, in modeling nonpeptidyl K. sup. + channel blockers, and in establishing biochemical assays based on ligand binding or other protocols with which to screen for other novel modulators of voltage dependent K. sup. + channels in lymphocytes and other tissues including the brain. As an immunosuppressant, MgTX is useful in the treatment of autoimmune diseases, the prevention of rejection of foreign organ transplants and/or related afflictions, diseases and illnesses.

US Patent:

46097422, Sep 2, 1986

Filed:

Feb 4, 1985

Appl. No.:

6/697806

Inventors:

Eugene D. Thorsett - Fanwood NJ
Joanne M. Williamson - Cranford NJ
Kenneth E. Wilson - Westfield NJ

Assignee:

Merck & Co., Inc. - Rahway NY

International Classification:

C07D31300

US Classification:

549271

Abstract:

The subject disclosure discloses a chemical intermediate in antibiotic synthesis of the structure: ##STR1## wherein R. sub. 1 is H or OH and the asterisks indicate asymmetric carbon atoms. Compounds of this type may be obtained by fermentation with a strain of B. subtilis under aerobic conditions. Compounds of the above structure are biologically inactive but are converted by phosphorylation of the hydroxyl group to produce compounds of the structure: ##STR2## wherein R. sub. 1 is H or OH, which are useful antibacterial substances having a broad spectrum of antibacterial activity.

US Patent:

44341580, Feb 28, 1984

Filed:

Apr 15, 1982

Appl. No.:

6/368903

Inventors:

Alton Meister - New York NY
Joanne M. Williamson - Roosevelt Island NY

Assignee:

Cornell Research Foundation - Ithaca NY

International Classification:

A61K 3754
A61K 31195
A61K 31425

US Classification:

424 94

Abstract:

L-2-oxothiazolidine-4-carboxylate, a sulfur analog of 5-oxoproline, is cleaved by the enzyme 5-oxo-L-prolinase to form cysteine, thus providing the basis for a cysteine delivery system by the addition of L-2-oxothiazolidine-4-carboxylate to base amino acid solutions or by injecting it directly into in vivo cells.

US Patent:

49977555, Mar 5, 1991

Filed:

Apr 14, 1988

Appl. No.:

7/181877

Inventors:

Joanne M. Williamson - Cranford NJ
David Houck - Los Alamos NM
Edward S. Inamine - Rahway NJ

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

C12P 1706
C12P 702
C12P 3306
C12N 120

US Classification:

435125

Abstract:

A microbiological process is described for the preparation of 6-desmethyl-6-. beta. -hydroxymethyl and 6-desmethyl-6-. beta. -carboxylovastatin derivatives and 8-acyl analogs thereof.

US Patent:

46475710, Mar 3, 1987

Filed:

Apr 15, 1982

Appl. No.:

6/368906

Inventors:

Alton Meister - New York NY
Joanne M. Williamson - Roosevelt Island NY

Assignee:

Cornell Research Foundation - Ithaca NY

International Classification:

A61K 3141

US Classification:

514369

Abstract:

L-2-oxothiazolidine-4-carboxylate, a sulfur analog of 5-oxoproline, is cleaved by the enzyme 5-oxo-L-prolinase to form cysteine, thus providing the basis for a cysteine delivery system by the addition of L-2-oxothiazolidine-4-carboxylate to base amino acid solutions or by injecting it directly into in vivo cells.